Novo Nordisk will invest $2.5 billion to construct three manufacturing facilities and expand its Kalundborg, Denmark site. According to Danish drugmaker Novo Nordisk, the expansion will support production of Novo Nordisk’s current and future injectable and oral products, including insulin. A spokesperson for Novo Nordisk told BioProcess Insider its Kalundborg site has been selected because the firm has “more than 50 years’ experience out of Kalundborg in Denmark; about 50 % of the total insulin production comes from Kalundborg; we…

Evolve Biologics has chosen Sachse, Texas as the site of its first plasma-derived therapeutics facility. Canadian-headquartered firm Evolve says the site selection and purchase of land establishes the company’s drive towards the commercialization of plasma-derived therapeutics. “Northern Texas has a growing corporate/pharmaceutical presence which enables collaboration and attracts a highly skilled workforce. The Dalls Fort Worth area also has a very strong educational base, including many high caliber and local universities, which is great for recruiting,” said David Holliday, Chief…

GenScript has opened its plasmid manufacturing plant in Zhenjiang, China, which will provide customers with a one-stop service, says firm. According to GenScript ProBio, its second plasmid facility is the largest one in China with a total floor space of 6,400 square-meter, which will support development of cell and gene therapies and messenger RNA (mRNA) drugs. Additionally, the firm claim the plant establishes its position in the contract development manufacturing organization (CDMO) field – providing more than double plasmid production…

Microbial manufacturing capacity will see steady growth over the next few years as molecular pipelines become more heterogenous, say experts. According to biotechnology group BDO’s Fall 2021 bioTRAK report covering the supply and demand of manufacturing capacity for recombinant biopharmaceuticals, current microbial manufacturing capacity totals more than 500kL. There are over 90 companies actively producing products for the global marketplace from 112 manufacturing plants, Dawn Ecker, managing director, bioTRAK Database Services told us. And “looking forward to 2025, microbial capacity…

BioMagnetic Solutions will build a ferrofluid and monoclonal antibody production facility at Innovation Park in Pennsylvania, US.   Gamma Biosciences acquired cell selection and bioseparation firm BioMagnetic Solutions (BMS) in January. Now BMS will construct a 13,000 square-foot production facility in Innovation Park at Penn State, which is expected to be fully operation in mid-2022. BMS claims the company will continue to focus on developing proprietary nanoscale ferrofluids from clinical to development through to commercial scale and the facility will…

The expansion at its Visp, Switzerland facility will support increased capacity of development services targeting microbial-derived proteins, says Lonza. The expansion will see Swiss contract development manufacturing organization (CDMO) Lonza up its microbial development laboratories at its Visp site by 50% as part of the firm’s focus on increasing its microbial service offerings. The investment, of which financial details have not been disclosed, will include the installation of a pilot suite with a 50 L fermenter and downstream equipment to…